Science, Scientific Research, Rare Disease.
develop a drug from initial discovery to completion, and less than 12 percent of drugs are approved once they’ve entered development,” said Tina Urv, PhD, program director for the Rare Diseases Clinical Research Network, a program at the National Institutes of Health, identifying one of the